Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIOยทNYSE

$304.83

+0.14%
HealthcareMedical - Devices

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

At a Glance

Live Snapshot
Market Cap$8.24B
EPS27.8700
P/E Ratio10.94
Earnings Date07/30/2026
Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. Fair Value Envelope

BIO ยท NYSE

Our analysis suggests that BIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $304.83, this represents a potential HIDDEN relative to our calculated worth for Bio-Rad Laboratories, Inc..

Intrinsic Value
Current Price: $304.83

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$148.3B
+ Cash & Equivalents$531.8M
Firm Value$148.8B
- Debt$1.5B
Equity Value$147.3B
/ Shares Outstanding26,974,708B
DCF Value$5.5K
UNDERVALUED BY 1691%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$748.9M
$1.1B
$1.5B
$2.1B
$2.9B
$4.1B
$5.8B
$8.2B
$11.5B
$16.2B
Maintenance CapEx
-$44.4M
-$62.4M
-$87.8M
-$123.6M
-$173.9M
-$244.8M
-$344.4M
-$484.7M
-$682.1M
-$959.8M
Owner Earnings
$704.6M
$991.5M
$1.4B
$2.0B
$2.8B
$3.9B
$5.5B
$7.7B
$10.8B
$15.2B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$652.4M
$850.0M
$1.1B
$1.4B
$1.9B
$2.5B
$3.2B
$4.2B
$5.4B
$7.1B
Terminal Value represents 81.0% of Enterprise Value